Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)

NCT07743671 is registered in ClinicalTrials.gov with Vaderis Therapeutics AG as lead sponsor.

NCT NCT07743671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07743671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
Lead sponsor
Vaderis Therapeutics AG
Phase
Phase 3
Overall status
Recruiting
Start date
September 30, 2026
Completion date
June 30, 2028
Enrollment
240 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary hemorrhagic telangiectasia